A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

Withdrawn before enrolling · Phase 1

Conditions studied: Locally Advanced Solid Tumor, Metastatic Solid Tumor

In brief

This is a Phase 1 study to evaluate the effect of moderate or severe hepatic impairment on the PK of repotrectinib in patients with advanced cancer.

Key facts

Study ID
NCT05828277
Run by
Turning Point Therapeutics, Inc.
People needed
0
Starts
2022-07-28
Expected to finish
2025-12-31
Last updated by the study team
2023-09-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.